Literature DB >> 24045165

Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis.

Alessandra Musella1, Georgia Mandolesi, Antonietta Gentile, Silvia Rossi, Valeria Studer, Caterina Motta, Helena Sepman, Diego Fresegna, Nabila Haji, Andrea Paolillo, Giuseppe Matarese, Diego Centonze.   

Abstract

Alterations of glutamate-mediated synaptic transmission occur in both multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE), the animal model of MS. Here we investigated whether intracerebroventricular (Icv) administration of cladribine has effects on EAE. Icv infusion of cladribine reduced the clinical deficits of EAE mice and reversed EAE-induced enhancement of excitatory postsynaptic current (sEPSC) frequency, a neurophysiological measure of glutamatergic synaptopathy associated with central inflammation. Cladribine failed to interfere with EAE-induced microglial and astroglial activation, but blocked EAE synaptic alterations by interfering with interleukin-1β effects. Cladribine possesses neuroprotective properties in experimental MS that are independent of its peripheral immunosuppressant action.
© 2013.

Entities:  

Keywords:  Cladribine; EAE; EPSC; IL-1β; Microglia; Striatum

Mesh:

Substances:

Year:  2013        PMID: 24045165     DOI: 10.1016/j.jneuroim.2013.08.009

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  9 in total

Review 1.  Oral Therapies for Multiple Sclerosis.

Authors:  Simon Faissner; Ralf Gold
Journal:  Cold Spring Harb Perspect Med       Date:  2019-01-02       Impact factor: 6.915

2.  Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration In Vitro Acutely Influences Monocyte Differentiation but Not Microglial Activation.

Authors:  Tiago Medeiros-Furquim; Sinan Ayoub; Laura J Johnson; Andrea Aprico; Eze Nwoke; Michele D Binder; Trevor J Kilpatrick
Journal:  Front Immunol       Date:  2022-06-06       Impact factor: 8.786

Review 3.  Focus on the Role of the NLRP3 Inflammasome in Multiple Sclerosis: Pathogenesis, Diagnosis, and Therapeutics.

Authors:  Yueran Cui; Haiyang Yu; Zhongqi Bu; Lulu Wen; Lili Yan; Juan Feng
Journal:  Front Mol Neurosci       Date:  2022-05-25       Impact factor: 6.261

Review 4.  Immune reconstitution therapies: concepts for durable remission in multiple sclerosis.

Authors:  Jan D Lünemann; Heinz Wiendl; Tobias Ruck; Paolo A Muraro; Amit Bar-Or
Journal:  Nat Rev Neurol       Date:  2019-10-24       Impact factor: 42.937

Review 5.  Role of Inflammasomes in Neuroimmune and Neurodegenerative Diseases: A Systematic Review.

Authors:  Yue Lang; Fengna Chu; Donghui Shen; Weiguanliu Zhang; Chao Zheng; Jie Zhu; Li Cui
Journal:  Mediators Inflamm       Date:  2018-04-17       Impact factor: 4.711

Review 6.  Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches.

Authors:  Francois Grand'Maison; Michael Yeung; Sarah A Morrow; Liesly Lee; Francois Emond; Brian J Ward; Pierre Laneuville; Robyn Schecter
Journal:  Neural Regen Res       Date:  2018-11       Impact factor: 5.135

7.  Cladribine Treatment Improved Homocysteine Metabolism and Increased Total Serum Antioxidant Activity in Secondary Progressive Multiple Sclerosis Patients.

Authors:  Anna Jamroz-Wiśniewska; Jerzy Bełtowski; Grażyna Wójcicka; Halina Bartosik-Psujek; Konrad Rejdak
Journal:  Oxid Med Cell Longev       Date:  2020-03-14       Impact factor: 6.543

8.  Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.

Authors:  Antonietta Gentile; Alessandra Musella; Silvia Bullitta; Diego Fresegna; Francesca De Vito; Roberta Fantozzi; Eleonora Piras; Francesca Gargano; Giovanna Borsellino; Luca Battistini; Anna Schubart; Georgia Mandolesi; Diego Centonze
Journal:  J Neuroinflammation       Date:  2016-08-26       Impact factor: 8.322

Review 9.  Glial Factors Regulating White Matter Development and Pathologies of the Cerebellum.

Authors:  Miren Revuelta; Till Scheuer; Li-Jin Chew; Thomas Schmitz
Journal:  Neurochem Res       Date:  2020-01-23       Impact factor: 3.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.